These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22555809)

  • 1. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.
    Ramos-Suzarte M; Lorenzo-Luaces P; Lazo NG; Perez ML; Soriano JL; Gonzalez CE; Hernadez IM; Albuerne YÁ; Moreno BP; Alvarez ES; Callejo IP; Alert J; Martell JA; Gonzalez YS; Gonzalez YS; Astudillo de la Vega H; Ruiz-Garcia EB; Ramos TC
    Cancer Biol Ther; 2012 Jun; 13(8):600-5. PubMed ID: 22555809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
    Yamamoto N; Harada H; Okamoto I; Masuda N; Hayakawa K; Satouchi M; Soejima T; Nishio M; Kozuka T; Takeda K; Tanaka M; Seto T; Sasaki T; Tsubouchi H; Kakurai Y; Nishimura Y; Nakagawa K
    Clin Lung Cancer; 2021 Mar; 22(2):134-141. PubMed ID: 33518480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial.
    de Castro Junior G; Segalla JG; de Azevedo SJ; Andrade CJ; Grabarz D; de Araújo Lima França B; Del Giglio A; Lazaretti NS; Álvares MN; Pedrini JL; Kussumoto C; de Matos Neto JN; Forones NM; Fernandes Júnior HJ; Borges G; Girotto G; da Silva IDCG; Maluf-Filho F; Skare NG
    Eur J Cancer; 2018 Jan; 88():21-30. PubMed ID: 29179134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.
    Lu M; Wang X; Shen L; Jia J; Gong J; Li J; Li J; Li Y; Zhang X; Lu Z; Zhou J; Zhang X
    Cancer Sci; 2016 Apr; 107(4):486-90. PubMed ID: 26797530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study.
    Kato K; Ura T; Koizumi W; Iwasa S; Katada C; Azuma M; Ishikura S; Nakao Y; Onuma H; Muro K
    Cancer Sci; 2018 Mar; 109(3):785-793. PubMed ID: 29285832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
    Jia J; Cui Y; Lu M; Wang X; Li J; Li J; Li Y; Zhang X; Gao J; Zhou J; Lu Z; Gong J; Yu J; Sun Z; Liu C; Shen L; Zhang X
    Clin Transl Oncol; 2016 Jun; 18(6):592-8. PubMed ID: 26459251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience.
    Xu S; Ramos-Suzarte M; Bai X; Xu B
    Oncotarget; 2016 May; 7(22):33391-407. PubMed ID: 27050148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma.
    Liang R; Yang L; Zhu X
    Cancer Control; 2021; 28():1073274821989301. PubMed ID: 33504193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
    Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
    BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
    Yang QY; Shen D; Sai K; Mu YG; Jiang XB; Zhang XH; Chen ZP
    Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):232-5. PubMed ID: 21575527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Kim SH; Shim HS; Cho J; Jeong JH; Kim SM; Hong YK; Sung JH; Ha SJ; Kim HR; Chang H; Kim JH; Tania C; Cho BC
    Lung Cancer; 2013 Mar; 79(3):270-5. PubMed ID: 23261229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer.
    Qi S; Mao Y; Jiang M
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1115-1123. PubMed ID: 31502113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of combined radiotherapy with EGFR inhibitors and chemotherapy for laryngeal organ preservation in patients with locally advanced hypopharyngeal carcinomas.
    Zhang X; Wang J; Wu W; Liu M; Zhao F; Du L; Huang D; Yang S; Ma L
    Curr Cancer Drug Targets; 2014; 14(6):589-98. PubMed ID: 25039274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
    Kim HR; Jang JS; Sun JM; Ahn MJ; Kim DW; Jung I; Lee KH; Kim JH; Lee DH; Kim SW; Cho BC
    Oncotarget; 2017 Feb; 8(9):15943-15951. PubMed ID: 27823977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nimotuzumab, an EGFR‑targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma.
    Yu Y; Guan H; Jiang L; Li X; Xing L; Sun X
    Int J Oncol; 2020 Apr; 56(4):945-956. PubMed ID: 32319582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective study comparing anti-EGFR monoclonal antibody plus cisplatin-based chemoradiotherapy versus chemoradiotherapy alone for stage II-IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression.
    Mao L; Tan J; Wang F; Luo Y; Liu W; Zeng F; Yu B; Huang H; Lu J; Peng X; Liu X
    Clin Otolaryngol; 2019 Jul; 44(4):572-580. PubMed ID: 30972891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR.
    Basavaraj C; Sierra P; Shivu J; Melarkode R; Montero E; Nair P
    Cancer Biol Ther; 2010 Oct; 10(7):673-81. PubMed ID: 20647773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
    Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W
    J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.
    Saumell Y; Sanchez L; González S; Ortiz R; Medina E; Galán Y; Lage A
    Adv Ther; 2017 Dec; 34(12):2638-2647. PubMed ID: 29134427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.
    Cetina L; Crombet T; Jiménez-Lima R; Zapata S; Ramos M; Avila S; Coronel J; Charco E; Bojalil R; Astudillo H; Bazán B; Dueñas-González A
    Cancer Biol Ther; 2015; 16(5):684-9. PubMed ID: 25802932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.